New data from ORIGIN
5 October 2012 | By Sanofi
New data from ORIGIN shows Lantus® use is about 3 times more likely to achieve and sustain target HbA1c vs. standard care over 5 years in the study population...
List view / Grid view
News
New data from a global survey find four in five people with type 2 diabetes have experienced hypoglycaemia
5 October 2012 | By Novo Nordisk
4/5 people with type 2 diabetes have experienced self-treated hypoglycaemia...
Final Phase IIb interferon-free hepatitis C data from Boehringer Ingelheim to be presented at AASLD
4 October 2012 | By Boehringer Ingelheim
New data from HCVersoTM have been accepted for presentation...
Shionogi-ViiV Healthcare announces completion of initial clinical registration package for dolutegravir in HIV
4 October 2012 | By GlaxoSmithKline
Dolutegravir is not yet approved as a treatment for HIV...
Pfizer announces top-line results of Prevenar 13® Phase 3 Trial in adults 18 to 49 years of age
4 October 2012 | By Pfizer
Pfizer has announced top-line data...
Phase IIb data showed investigational once-weekly DPP-4 inhibitor MK-3102 significantly lowered blood sugar in patients with type 2 diabetes
3 October 2012 | By Merck
Phase III trials of MK-3102 underway...
New analysis shows Victoza® is more effective when used early in the management of type 2 diabetes
3 October 2012 | By Novo Nordisk
"We know from clinical practice that liraglutide is highly effective..."
Sanofi and Bristol-Myers Squibb announce restructuring of alliance agreement
3 October 2012 | By Bristol-Myers Squibb Company
Sanofi & Bristol-Myers Squibb have restructured their long-term alliance...
TECAN and JPT Peptide Technologies announce cooperation agreement
2 October 2012 | By kdm communications limited
TECAN and JPT Peptide Technologies GmbH announced a collaborative agreement between the two specialist companies...
Investigational insulin degludec shows 43% lower rates of night-time hypoglycaemia
2 October 2012 | By Novo Nordisk
Than insulin glargine in a 2-year study investigating people with type 2 diabetes...
Lilly and Boehringer Ingelheim present health outcomes data for investigational novel basal insulin analogue
2 October 2012 | By Boehringer Ingelheim
Patient-reported health outcomes data from a Phase II study...
Clinical data for investigational SGLT2 inhibitor, empagliflozin*, demonstrates potential for oral treatment in type 2 diabetes
2 October 2012 | By Boehringer Ingelheim
Results of a pooled analysis...
Analyses presented at EASD support Trajenta® (linagliptin) as effective and well-tolerated for patients with type 2 diabetes with different background therapies
2 October 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company today announced results from a large Phase III study and three pooled analyses of Phase III data presented at the 48th European Association for the Study of Diabetes (EASD) Annual Meeting, which support Trajenta® (linagliptin) as effective and well-tolerated for patients with type…
Roche’s trastuzumab emtansine (T-DM1) significantly extended survival in people with aggressive form of breast cancer
1 October 2012 | By Roche
Updated survival results from the Phase III EMILIA study...
Merck to present new data for VICTRELIS® (boceprevir) and MK-5172 at The AASLD 2012 Annual Meeting
1 October 2012 | By Merck
New data from Phase III studies...
